Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent (TD) thalassemia is caused by a mutation in both HBB genes, although some patients with mutations in both genes are classified as having non-transfusion-dependent (NTD) thalassemia. Patients can present with jaundice, bone deformities, and chronic anemia. Management of BT was once limited to regular blood transfusions and iron chelators, but therapies such as BMS’s Reblozyl, Bluebird Bio’s Zynteglo, and Vertex / CRISPR Therapeutics’ Casgevy now offer a more promising future for BT patients. Nevertheless, strong unmet need remains for universally curative therapies that improve BT patients’ quality of life. In this report, we examine the current treatment of BT in the United States and EU5 countries and the agents in development, including those that target the underlying genetic defect and reduce the transfusion burden.
Questions answered
- How large is the diagnosed BT population in the United States and EU5? How will the population change through 2034?
- What is the current landscape for BT patients, and how will it change over the next 10 years considering alternative therapies, such as Zynteglo and Casgevy, are now available?
- What pipeline products are most promising, and what sales / uptake could they secure in BT? How will emerging therapies affect medical practice?
Product description
Niche & Rare Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Content highlights
Publication date September 2025
Geography United States, EU5
Primary research
Country-specific interviews with thought-leading hematologists
Survey data collected for this and other Clarivate research
Epidemiology
Diagnosed prevalent and drug-treatable cases of beta thalassemia by country, segmented by severity, genotype, and availability of HLA-matched sibling HSCT donor
Forecast
Drug-level sales and patient share of key beta thalassemia therapies in 2024 and 2034
Drug treatments
Coverage of key current and late-phase emerging therapies
Table of contents
- Beta Thalassemia - Landscape & Forecast - Niche & Rare Disease Landscape & Forecast (US/EU5)
- Content announcement
- Executive Summary
- Commercial Outlook and Forecast
- Disease Context
- Epidemiology
- Key takeaways
- Diagnosed prevalent cases of beta thalassemia
- Beta thalassemia by severity
- Beta thalassemia major by genotype
- Diagnosed prevalent cases of beta thalassemia major by HSC transplantation
- Disease definition and methods
- Diagnosed prevalent cases of beta thalassemia major genotype B0/B0 in the major pharmaceutical markets by status of matched related HSCT, 2024-2034
- Diagnosed prevalent cases of beta thalassemia major genotype B+/B+ in the major pharmaceutical markets by status of matched related HSCT, 2024-2034
- Diagnosed prevalent cases of beta thalassemia major genotype B0/B+ in the major pharmaceutical markets by status of matched related HSCT, 2024-2034
- Diagnosed prevalent cases of beta thalassemia intermedia by the need for transfusion
- Diagnosed and drug-treated populations
- Key takeaways
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast key events and assumptions
- Market events impacting the beta thalassemia forecast
- Drug treatment rate assumptions in beta thalassemia
- Forecast market authorization and/or launch dates of key emerging therapies for the treatment of beta thalassemia
- Dosing assumptions of key therapies in beta thalassemia
- Days of therapy and compliance
- Emerging therapy prices
- Prices of key current and emerging therapies used to treat beta thalassemia
- Bottom-up forecast methodology
- Primary market research
- Appendix
